Buscar

23/11/2021 Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Dickinson, M, Briones, J, Herrera, AF, Gonzalez-Barca, E, Ghosh, N, Cordoba, R, Rutherford, SC, Bournazou, E, Labriola-Tompkins, E, Franjkovic, I, Chesne, E, Brouwer-Visser, J, Lechner, K, Brennan, B, Nuesch, E, DeMario, M, Ruttinger, D, Kornacker, M, Hutchings, M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 2021; 5(22)DOI:10.1182/bloodadvances.2021004619. PMID:34581757. IF:7.642(Q1/3D).
01/01/2023 High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion
Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00518-6. PMID:36031661. IF:4.800(Q1/2D).
01/01/2023 Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
Del Principe, MI, Seidel, D, Criscuolo, M, Dargenio, M, Racil, Z, Piedimonte, M, Marchesi, F, Nadali, G, Koehler, P, Fracchiolla, N, Cattaneo, C, Klimko, N, Spolzino, A, Karapinar, DY, Demiraslan, H, Duarte, RF, Demeter, J, Stanzani, M, Melillo, LMA, Basilico, CM, Cesaro, S, Paterno, G, Califano, C, Delia, M, Buzzatti, E, Busca, A, Cornely, OA, Pagano, L, Alakel, N, Arsenijevi'c, VA, Camus, V, Falces-Romero, I, Itzhak, L, Kouba, M, Martino, R, Sedlacek, P, Weinbergerova, B. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope. MYCOSES. 2023; 66(1)DOI:10.1111/myc.13524. PMID:36064299. IF:4.100(Q1/2D).
01/12/2022 5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics
Diaz-Santa, J, Rodriguez-Romanos, R, Coll, R, Osca, G, Pratcorona, M, Gonzalez-Bartulos, M, Garrido, A, Angona, A, Talarn, C, Tormo, M, Arnan, M, Vives, S, Salamero, O, Tuset, E, Lloveras, N, Diez, I, Zamora, L, Bargay, J, Sampol, A, Cruz, D, Vila, J, Sitges, M, Garcia, A, Vall-Llovera, F, Esteve, J, Sierra, J, Gallardo, D. 5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. EUROPEAN JOURNAL OF HAEMATOLOGY. 2022; 109(6)DOI:10.1111/ejh.13862. PMID:36063368. IF:3.100(Q3/6D).
01/12/2022 Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
Baptista, MJ, Tapia, G, Munoz-Marmol, AM, Muncunill, J, Garcia, O, Montoto, S, Gribben, JG, Calaminici, M, Martinez, A, Veloza, L, Martinez-Trillos, A, Aldamiz, T, Menarguez, J, Terol, MJ, Ferrandez, A, Alcoceba, M, Briones, J, Gonzalez-Barca, E, Climent, F, Muntanola, A, Moraleda, JM, Provencio, M, Abrisqueta, P, Abella, E, Colomo, L, Garcia-Ballesteros, C, Garcia-Caro, M, Sancho, JM, Ribera, JM, Mate, JL, Navarro, JT. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. HISTOPATHOLOGY. 2022; 81(6)DOI:10.1111/his.14798. PMID:36109172. IF:6.400(Q1/2D).
01/12/2022 mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
Albiol, N, Barata, A, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. SUPPORTIVE CARE IN CANCER. 2022; 30(12)DOI:10.1007/s00520-022-07376-w. PMID:36169731. IF:3.100(Q1/3D).